DARBEPOETIN ALFA

Other

Brand names: ARANESP

Intravenous, Subcutaneous

12.1 Mechanism of Action Aranesp stimulates erythropoiesis by the same mechanism as endogenous erythropoietin.

and upon initiation

there is a minimum of two additional months of planned chemotherapy ( 1.2 ). Limitations of Use Aranesp has not been shown to improve quality of life

fatigue

or patient well-being ( 1.3 ). Aranesp is not indicated for use: In patients with cancer receiving hormonal agents

biologic products

or radiotherapy

5 WARNINGS AND PRECAUTIONS Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism: Using Aranesp to target a hemoglobin level of greater than 11 g/dL increases the risk of serious adverse cardiovascular reactions and has not been shown to provide additional benefit ( 5
Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence in Patients with Cancer ( 5
Seizures: Aranesp increases the risk for seizures in patients with CKD ( 5
Serious Allergic Reactions: Discontinue Aranesp and manage reactions ( 5

7 documented side effects by frequency

Fatigue

0.1-1%

Shortness of Breath

0.1-1%

Diarrhea

0.1-1%

Nausea

0.1-1%

Falls

0.1-1%

Weakness

0.1-1%

Vomiting

0.1-1%

No community discussions found for DARBEPOETIN ALFA yet.

0 available comparisons

No comparisons yet.

Dosage Forms

Tablet

Route

Intravenous, Subcutaneous